S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Are Gene Therapy Stocks The Market's Next Big Winners?
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Options Trading Plan–Perfect For Beginners (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Are Gene Therapy Stocks The Market's Next Big Winners?
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Options Trading Plan–Perfect For Beginners (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Are Gene Therapy Stocks The Market's Next Big Winners?
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Options Trading Plan–Perfect For Beginners (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Are Gene Therapy Stocks The Market's Next Big Winners?
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Options Trading Plan–Perfect For Beginners (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
NASDAQ:VTVT

vTv Therapeutics (VTVT) Stock Forecast, Price & News

$0.45
+0.01 (+2.27%)
(As of 09/25/2023 ET)
Compare
Today's Range
$0.44
$0.46
50-Day Range
$0.42
$0.74
52-Week Range
$0.41
$1.05
Volume
80,239 shs
Average Volume
136,285 shs
Market Capitalization
$47.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

vTv Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,233.0% Upside
$6.00 Price Target
Short Interest
Healthy
4.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

829th out of 962 stocks

Pharmaceutical Preparations Industry

394th out of 451 stocks


VTVT stock logo

About vTv Therapeutics (NASDAQ:VTVT) Stock

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

VTVT Price History

VTVT Stock News Headlines

vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com
Surprising "Twist" Hands Biden Landslide Re-election?
This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com
Is vTv Therapeutics Inc (VTVT) Modestly Undervalued?
Surprising "Twist" Hands Biden Landslide Re-election?
This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.
VTVT - vTv Therapeutics Inc.
vTv Therapeutics Insider Ups Holding During Year
vTv Therapeutics Insider Ups Holding During Year \
vTv Therapeutics Inc Class A
See More Headlines
Receive VTVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTVT Company Calendar

Last Earnings
8/11/2023
Today
9/25/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTVT
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+1,221.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-19,160,000.00
Pretax Margin
-272,700.00%

Debt

Sales & Book Value

Annual Sales
$2.02 million
Book Value
($0.10) per share

Miscellaneous

Free Float
103,740,000
Market Cap
$47.49 million
Optionable
Not Optionable
Beta
-1.13
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Jonathan L. Isaacsohn FACC (Age 69)
    M.D., Exec. Chairperson
  • Mr. Paul J. Sekhri M.Sc. (Age 65)
    MSc, CEO, Pres & Director
    Comp: $483.43k
  • Mr. Steven Tuch M.B.A. (Age 54)
    Exec. VP & CFO
    Comp: $449.16k
  • Mr. Barry Brown (Age 62)
    Chief Accounting Officer
    Comp: $311.98k
  • Mr. Richard S. Nelson (Age 53)
    Exec. VP of Corp. Devel. & Director
    Comp: $201.08k
  • Dr. Carmen Valcarce Ph.D.
    Chief Scientific Officer & Exec. VP
  • Vanessa McDade
    Chief Admin. Officer
  • Ms. Elizabeth M. Keiley (Age 57)
    Exec. VP & Gen. Counsel













VTVT Stock - Frequently Asked Questions

Should I buy or sell vTv Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VTVT shares.
View VTVT analyst ratings
or view top-rated stocks.

What is vTv Therapeutics' stock price forecast for 2023?

1 brokerages have issued 1 year price objectives for vTv Therapeutics' shares. Their VTVT share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 1,221.3% from the stock's current price.
View analysts price targets for VTVT
or view top-rated stocks among Wall Street analysts.

How have VTVT shares performed in 2023?

vTv Therapeutics' stock was trading at $0.6628 on January 1st, 2023. Since then, VTVT shares have decreased by 31.5% and is now trading at $0.4541.
View the best growth stocks for 2023 here
.

When is vTv Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our VTVT earnings forecast
.

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc. (NASDAQ:VTVT) issued its earnings results on Friday, August, 11th. The biotechnology company reported ($0.07) earnings per share for the quarter.

What other stocks do shareholders of vTv Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA).

When did vTv Therapeutics IPO?

(VTVT) raised $125 million in an IPO on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

How do I buy shares of vTv Therapeutics?

Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is vTv Therapeutics' stock price today?

One share of VTVT stock can currently be purchased for approximately $0.45.

How much money does vTv Therapeutics make?

vTv Therapeutics (NASDAQ:VTVT) has a market capitalization of $47.49 million and generates $2.02 million in revenue each year. The biotechnology company earns $-19,160,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

How can I contact vTv Therapeutics?

vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The official website for the company is www.vtvtherapeutics.com. The biotechnology company can be reached via phone at (336) 841-0300, via email at ir@vtvtherapeutics.com, or via fax at 336-841-0310.

This page (NASDAQ:VTVT) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -